Navigation Links
Dasatinib Shows High Early Response Rate as First Treatment for,Chronic Myelogenous Leukemia, M. D. Anderson Researchers Report

CHICAGO, June 2, 2007 - An established second-line drug for chronic myelogenous leukemia has high response rates when given to newly diagnosed patients as their first therapy for the disease, according to early results from a Phase II clinical trial at The University of Texas M. D. Anderson Cancer Center.

"Patients taking dasatinib achieve complete cytogenetic response - absence of the mutated protein that drives this disease - more rapidly than we've observed historically using the current front-line therapy. Side effects are very manageable," says Ehab L. Atallah, M.D., lead author of the study and a fellow in M. D. Anderson's Department of Leukemia. Atallah presented study results at the annual meeting of the American Society of Clinical Oncology in Chicago Saturday June 2nd, 2007. The clinical trial remains in progress with 35 patients enrolled.

Dasatinib, known commercially as Sprycel and produced by Bristol-Myers Squibb, was approved by the U.S. Food and Drug Administration a year ago for use by patients whose disease is unresponsive to or becomes resistant to the front-line therapy imatinib. Both drugs bind to and block a genetically flawed protein known as BCR-ABL, which causes the disease. Atallah explains that dasatinib binds to both forms BCR-ABL while imatinib blocks only one.

"Our hypothesis is that treating with dasatinib first will produce an earlier response, which may translate to a better overall survival," Atallah says. "We haven't proved that here, but these early results are encouraging."

Atallah and colleagues evaluated 35 patients who enrolled in the clinical trial between November 2005 and December 2006. Patients receive either 100 mg of dasatinib once daily or 50 mg twice daily.

Thirty four patients had been on the clinical trial for at least three months when Atallah and lead researcher Jorge Cortes, M.D., professor in the Department of Leukemia, eva
'"/>




Page: 1 2 3

Related medicine technology :

1. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
2. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
3. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
4. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
5. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
6. Ceragenix Compound Shows Promise for Treating Lethal Cystic Fibrosis Infections
7. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
8. CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and Pain, but Not CRP
9. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
10. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
11. New Poll Shows Men, Women Incorrectly Blame Symptoms of Low Testosterone on Normal Aging

Post Your Comments:
(Date:11/25/2009)...Newswire-FirstCall/--Pharmasset,Inc.(Nasdaq: VRUS ...scovering,developingandcommercializingnoveldrugsto...efiscalyearendedSeptember30,2009.AtSeptember30,200...ndshortterminvestments. ,, PipelineUpdateand20... ,, InlateNovember2009,anindependentDataMonito...
(Date:11/25/2009)...ire/--BioTrendsResearchGroup,Inc.releasedWave1ofit...amulti-phasesyndicatedmarketresearchprojecttrackin...ductlaunchthroughthefirstsixmonthsofavailability.E...rom75uniqueDermatologistsandqualitativeinformation...ra,obstaclestouse,typicalpatienttypes,productperce...
(Date:11/25/2009)...RNewswire-USNewswire/--RemediumTechnologiesInc.,ac...erebleeding,wonfirstprizeand$10,000intheMostPromis...e2009,companyofficialsannouncetoday. ,, Selecte...,steampitchedtheirinventionattheGSCSecuritySummitc...medium( www.remediumtechnologies.com )isdeveloping...
Breaking Medicine Technology:Pharmasset Reports Fiscal Year End 2009 Financial Results 2Pharmasset Reports Fiscal Year End 2009 Financial Results 3Pharmasset Reports Fiscal Year End 2009 Financial Results 4Pharmasset Reports Fiscal Year End 2009 Financial Results 5Pharmasset Reports Fiscal Year End 2009 Financial Results 6Pharmasset Reports Fiscal Year End 2009 Financial Results 7Pharmasset Reports Fiscal Year End 2009 Financial Results 8Despite Managed Care Obstacles, Interest and Anticipated Use of Centocor Ortho-Biotech's New Psoriasis Agent Stelara (ustekinumab) is High 2Remedium Technologies Wins Most Promising Security Idea at Global Security Challenge 2009 with Blood-Clotting Foam 2Remedium Technologies Wins Most Promising Security Idea at Global Security Challenge 2009 with Blood-Clotting Foam 3Shire Builds Competitive Position of its HGT Business through Research Collaboration with Santaris Pharma A S on LNA Drug Platform 13659 1Shire Builds Competitive Position of its HGT Business through Research Collaboration with Santaris Pharma A S on LNA Drug Platform 13659 2Shire Builds Competitive Position of its HGT Business through Research Collaboration with Santaris Pharma A S on LNA Drug Platform 13659 3Shire Builds Competitive Position of its HGT Business through Research Collaboration with Santaris Pharma A S on LNA Drug Platform 13659 4Bavarian Nordic in Negotiations With the US Authorities for the Further Development of IMVAMUNE 28R 29 13656 1Bavarian Nordic in Negotiations With the US Authorities for the Further Development of IMVAMUNE 28R 29 13656 2Santaris Pharma A S Forms Strategic Alliance With Shire plc to Develop RNA Based Medicines for the Treatment of Rare Genetic Disorders 13655 1Santaris Pharma A S Forms Strategic Alliance With Shire plc to Develop RNA Based Medicines for the Treatment of Rare Genetic Disorders 13655 2Santaris Pharma A S Forms Strategic Alliance With Shire plc to Develop RNA Based Medicines for the Treatment of Rare Genetic Disorders 13655 3Santaris Pharma A S Forms Strategic Alliance With Shire plc to Develop RNA Based Medicines for the Treatment of Rare Genetic Disorders 13655 4
...SAN MATEO, Calif., Jan. 8 Corthera Inc. today ann...hase II clinical trial of,Relaxin, a naturally occ...,acute heart failure and other acute care illnesse...afety of Relaxin in,patients with acute heart fail...from more than 50 investigational centers worldwid...
...DEERFIELD, Ill., Jan. 7 Baxter International,Inc....ed pre-clinical,programs to develop recombinant Fa...l develop both an unmodified recombinant Factor IX...and a chemically modified, long-acting,version of ...leeding in,hemophilia B patients. Hemophilia B is ...
Other Medicine Technology:Corthera Initiates Phase II Clinical Trial of Relaxin in Acute Heart Failure 2Baxter Announces Recombinant Factor IX Development Program For Hemophilia B 2Baxter Announces Recombinant Factor IX Development Program For Hemophilia B 3
(Date:11/26/2009)... Research Triangle Dental (...ral North Carolina, today announced the expansion ...d LUMINEER Dentist, Dr. Doug Macmillan. , ... Triangle Dental is pleased to announce that Dr. D... recently completed an additional advanced trainin...
(Date:11/25/2009)...,, KANSASCITY,Mo.,Nov.25/PRNewswire/--TheBartle...,slargestmedicalcliniconDec.9-10,whenKansasCityhos...edpeople. ,, "Thisfreecliniceventhasthepotentia...ysinsteadofjustoneandbeheldonweekdaysinsteadofover...tyFreeHealthClinicandpresidentoftheNationalAssocia...
(Date:11/25/2009)...,, LONGBEACH,Calif.,Nov.25/PRNewswire/--Thanksg...oundseniorsinthegreaterLongBeachareathankstoFaithI...IndependenceatHome(IAH),adivisionofSCANHealthPlan....ndredsofvolunteerstodeliverwarmThanksgivingmealsto...Bay,SouthLosAngelesandsurroundingcities. ,, "Ou...
(Date:11/25/2009)...,, BroadPoliticalEndorsements,Business,andPres...RNewswire-USNewswire/--Onceagain,theNationalBipola...amationendorsingtheir"Safe,tilStable"program,which...sureforbipolardisorder.Today,theNationalBipolarFou...lExpressPriorityMailfromtheLt.GovernorofLouisianaM...
(Date:11/25/2009)...Does stress increase blood pressure? This simple ...r many years. New Stress-related gene Modulates H...rease blood pressure? This simple question has be...Now new research has for the first time establishe...blood pressure response to stress in mice as well ...
Breaking Medicine News(10 mins):Health News:Dr. Douglas Macmillan Now Providing LUMINEERS at Research Triangle Dental 2Health News:Kansas City Prepares for Largest Free Health Clinic 2Health News:SCAN Employees and Community Volunteers to Help Deliver One Thousand Thanksgiving Meals to Homebound Seniors 2Health News:First Time-Door is Open for Family Discussion of Bipolar Disorder 2Health News:First Time-Door is Open for Family Discussion of Bipolar Disorder 3Health News:New stress-related gene modulates high blood pressure in mice and men 2
... A new study led by Volker Heussler of the Bernhar..., Germany, has found that the malarial //parasite ... occupied by them. Till now it was known that...mune system. Heussler's team used a technique call...
... according to the research conducted by the stem c...from the Burnham Institute //for Medical Research ...ic stem cell research has inherent characteristics...s could be later used to replace diseased or damag...
... Research study on Rheumatic disease in women has ...id arthritis in women who have no genetic predispo...s is an autoimmune disease, which causes chronic i...une system to attack the body’s own tissues result...
... Giving up your regular late-night snack may be ha... may genetically change an area of the brain to ex...uthwestern Medical Center have discovered. B...ain. Even when the food stopped coming, the genes ...
... UCLA researchers found that altering the fatty ac...ude more omega-3 fatty acids and decrease the amou...ncer tumor growth rates and PSA levels. Publi...wering an inflammatory response known to promote p...
... Each year, about 40,000 children are born infecte...000 of these children suffer permanent disabilitie...abilities// can include hearing loss, vision loss,...ious disability as Down syndrome, fetal alcohol sy...
Other Medicine News:Health News:Human Embryonic Stem Cells Could Be Later Used In Therapeutic Cloning 2Health News:Timing of Food Consumption Activates Genes in Specific Brain Area 2Health News:Altering Fatty Acid Levels in Diet May Reduce Prostate Cancer Growth Rate 2Health News:Innovative Method for Creating a Human Cytomegalovirus Vaccine Outlined 2
...ional reference laboratory and a worldwide leader ... ARUP offers an extensive test menu of highly comp...mic pathology. Owned by the University of Utah, AR... the nation's university teaching hospitals and ch...
...ional reference laboratory and a worldwide leader ... ARUP offers an extensive test menu of highly comp...mic pathology. Owned by the University of Utah, AR... the nation's university teaching hospitals and ch...
...ional reference laboratory and a worldwide leader ... ARUP offers an extensive test menu of highly comp...mic pathology. Owned by the University of Utah, AR... the nation's university teaching hospitals and ch...
...ional reference laboratory and a worldwide leader ... ARUP offers an extensive test menu of highly comp...mic pathology. Owned by the University of Utah, AR... the nation's university teaching hospitals and ch...
Medicine Products: